Parmax Pharma
BSE: PARMAX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Parmax Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Parmax Pharma Limited is a Gujarat-based pharmaceutical company specialising in the manufacturing and marketing of generic formulations and bulk drugs. Its product portfolio encompasses tablets, capsules, and liquid orals across therapeutic categories including anti-infectives, analgesics, and gastrointestinal treatments.
Business Model
The company generates revenue through contract manufacturing services and the distribution of generic medicines via a broad network of stockists. It serves both the ethical and PCD franchise markets within India.
Growth Outlook
Growth is driven by the company's focus on affordable healthcare solutions and its established presence in the regional pharmaceutical manufacturing landscape. Future expansion relies on leveraging its existing manufacturing infrastructure to cater to domestic demand.
Key Risks
- Regulatory Compliance. Changes in domestic pharmaceutical regulations or quality standards could necessitate costly upgrades to manufacturing facilities.
- Market Competition. The company faces intense competition from larger pharmaceutical firms that benefit from greater economies of scale and wider distribution networks.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials may adversely impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Parmax Pharma and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Parmax PharmaPARMAX | ₹49 Cr | — | — | — | -30.1% | — | — | +269.5% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Parmax Pharma
BSE: PARMAX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Parmax Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Parmax Pharma Limited is a Gujarat-based pharmaceutical company specialising in the manufacturing and marketing of generic formulations and bulk drugs. Its product portfolio encompasses tablets, capsules, and liquid orals across therapeutic categories including anti-infectives, analgesics, and gastrointestinal treatments.
Business Model
The company generates revenue through contract manufacturing services and the distribution of generic medicines via a broad network of stockists. It serves both the ethical and PCD franchise markets within India.
Growth Outlook
Growth is driven by the company's focus on affordable healthcare solutions and its established presence in the regional pharmaceutical manufacturing landscape. Future expansion relies on leveraging its existing manufacturing infrastructure to cater to domestic demand.
Key Risks
- Regulatory Compliance. Changes in domestic pharmaceutical regulations or quality standards could necessitate costly upgrades to manufacturing facilities.
- Market Competition. The company faces intense competition from larger pharmaceutical firms that benefit from greater economies of scale and wider distribution networks.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials may adversely impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Parmax Pharma and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026